RT Journal Article
SR Electronic
T1 A household case evidences shorter shedding of SARS-CoV-2 in naturally infected cats compared to their human owners
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.31.20220608
DO 10.1101/2020.10.31.20220608
A1 Neira, Víctor
A1 Brito, Bárbara
A1 Agüero, Belén
A1 Berrios, Felipe
A1 Valdés, Valentina
A1 Gutierrez, Alberto
A1 Ariyama, Naomi
A1 Espinoza, Patricio
A1 Retamal, Patricio
A1 Holmes, Edward C.
A1 Gonzalez-Reiche, Ana S.
A1 Khan, Zenab
A1 van de Guchte, Adriana
A1 Dutta, Jayeeta
A1 Miorin, Lisa
A1 Kehrer, Thomas
A1 Galarce, Nicolás
A1 Almonacid, Leonardo I.
A1 Levican, Jorge
A1 van Bakel, Harm
A1 García-Sastre, Adolfo
A1 Medina, Rafael A.
YR 2020
UL http://medrxiv.org/content/early/2020/11/04/2020.10.31.20220608.abstract
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been detected in domestic and wild cats. However, little is known about natural viral infections of domestic cats, although their importance for modeling disease spread, informing strategies for managing positive human-animal relationships and disease prevention. Here, we describe the SARS-CoV-2 infection in a household of two human adults and sibling cats (one male and two females) using real-time RT-PCR, an ELISA test, viral sequencing, and virus isolation. On May 2020, the cat- owners tested positive for SARS-CoV-2. Two days later, the male cat showed mild respiratory symptoms and tested positive. Four days after the male cat, the two female cats became positive, asymptomatically. Also, one human and one cat showed antibodies against SARS-CoV-2. All cats excreted detectable SARS-CoV-2 RNA for a shorter duration than humans and viral sequences analysis confirmed human-to-cat transmission. We could not determine if cat-to-cat transmission also occurred.Article Summary Line SARS-CoV-2 in naturally infected cats present a shorter shedding pattern compared to their owners.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partly funded by the Programa Fondecyt de Iniciacion N 11170877 and Proyecto FIV to VN; the Programa Beca Magister Nacional de ANID N 22190312 to NA. These studies were partly supported by CRIP (Center for Research for Influenza Pathogenesis), a NIAID supported Center of Excellence for Influenza Research and Surveillance (CEIRS, contract # HHSN272201400008C) to VN, RAM, HVB, and AG-S; by the generous support of the JPB Foundation, the Open Philanthropy Project (research grant 2020 215611 (5384)); and by anonymous donors to AG-S. This research was also partly supported by the Office of Research Infrastructure of the National Institutes of Health (NIH) under award numbers S10OD018522 and S10OD026880. ASG-R. was further supported by a Robin Chemers Neustein Postdoctoral Fellowship Award. Human protocols and the study set-up used for this study were based on influenza virus studies established in part with the support of the FONDECYT 1161971 grant to RAM and by grant ACT 1408 to RAM and VN from the Agencia Nacional de Investigacion y Desarrollo (ANID) from Chile.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The animal study was reviewed and approved by the Institutional Animal Care and Use Committee of Universidad de Chile, under protocol number 20370 VET UCH, Biosafety Committee of Facultad de Ciencias Veterinarias y Pecuarias, Universidad de Chile under protocol number 161 and the human study was reviewed and approved under protocol 16066 Scientific Ethical Committee on Health Sciences of Pontifical Universidad Catolica de Chile.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequences that support the results of this study have been deposited at GenBank with accession numbers MW064259 - MW064264.